http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Beihua Kong (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
ASGO 7th International Workshop on Gynecologic Oncology
Jie Yang,Yang Xiang,Beihua Kong 대한부인종양학회 2022 Journal of Gynecologic Oncology Vol.33 No.6
The 7th International Workshop of the Asian Society of Gynecologic Oncology (ASGO) was held by the Chinese Society of Gynecologic Oncology (CSGO) and Peking Union Medical College Hospital on 27th to 28th August 2022. The 2022 workshop was the first ASGO congress that was held in mainland China. Due to the COVID situation, this workshop was conducted virtually. Five hundred eighty-seven participants from 13 countries/regions (Hong Kong, India, Indonesia, Italy, Japan, Korea, Mainland China, Malaysia, Singapore, Taiwan, Thailand, United Kingdom, and United State of America) attended the meeting (Table 1). Dr. Beihua Kong (Shandong, China), president of CSGO, served as the president. Dr. Yang Xiang, president-elect of Chinese Medical Association (CMA) Gynecologic Oncology division, served as the executive president of the 7th ASGO workshop. Following the 18th ASGO council meeting on August 26th (Fig. 1), the workshop was grandly held on August 27th and 28th virtually.
-
PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer
Ma Hanlin,Qi Gonghua,Han Fang,Peng Jiali,Yuan Cunzhong,Kong Beihua 생화학분자생물학회 2022 Experimental and molecular medicine Vol.54 No.-
Resistance to PARP inhibitors (PARPi) remains a therapeutic challenge in ovarian cancer patients. PDZ-binding kinase (PBK) participates in the chemoresistance of many malignancies. However, the role of PBK in PARPi resistance of ovarian cancer is obscure. In the current study, we demonstrated that overexpression of PBK contributed to olaparib resistance in ovarian cancer cells. Knockdown of PBK sensitized olaparib-resistant SKOV3 cells to olaparib. Inhibition of PBK using a specific inhibitor enhanced the therapeutic efficiency of olaparib. Mechanically, PBK directly interacted with TRIM37 to promote its phosphorylation and nuclear translocation. which subsequently activates the NFκB pathway. Additionally, PBK enhanced olaparib resistance of ovarian cancer by regulating the NFκB/TRIM37 axis in vitro and in vivo. In conclusion, PBK confers ovarian cancer resistance to PARPi through activating the TRIM37-mediated NFκB pathway, and targeted inhibition of PBK provided the new therapy to improve PARPi treatment outcomes for ovarian cancer patients.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
